iPath Pure Beta Sugar ETN
SGAR
SGAR was delisted on the 11th of April, 2018.
1 hedge funds and large institutions have $33K invested in iPath Pure Beta Sugar ETN in 2017 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
3% less capital invested
Capital invested by funds: $34K → $33K (-$1K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.27K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $33K | -$2.27K | -100 | -6% |
|
SGAR Hedge Fund Activity: Q4 2017 in Review
1 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in iPath Pure Beta Sugar ETN (SGAR) for Q4 2017, worth a combined $33K — down 2.9% from $34K a quarter earlier.
Fund positioning in SGAR was balanced in Q4 2017: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was UBS Group, cutting an estimated $2.27K.
- 1 institutional investor held iPath Pure Beta Sugar ETN (SGAR) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $33K of iPath Pure Beta Sugar ETN stock for Q4 2017, down 2.9% quarter-over-quarter.
- 0 funds opened new iPath Pure Beta Sugar ETN positions in Q4 2017 and 0 closed out.
- The largest iPath Pure Beta Sugar ETN seller in Q4 2017 was UBS Group, an estimated $2.27K sold.
Based on aggregated 13F filings for Q4 2017.